Christopher Glisson

Biography

 Education and Professional Positions:  D.O., Michigan State University College of Osteopathic Medicine 2002 M.S., Neurophysiology, Wayne State University 1998 B.S., Hillsdale College 1995 Selected Publications:  Miller AF, Wolinski JS, Kappos I. and the TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Neurology 2014 (in press, e-pub 09/02/2014). Prasad S, Moss HE, Lee EB, Glisson CC, and Galetta SL. Clinical Reasoning: A 42-year-old man with sequential monocular visual loss. Neurology 2008;71:e43-e49. Glisson CC and Galetta SL. Drawing the line between NMO and MS. Practical Neurology 2007:32-37. Glisson CC. Capturing the benefit of vision restoration therapy. Current Opinion in Ophthalmology 2006;17(6):504-8. Glisson CC, Eggenberger ER and Miller N. Supranuclear ophthalmoplegia as a complication of coronary angiography. Neuro-Ophthalmology 2006;30(4):101-103. Glisson CC, Mohler ER3rd and Majid A. An unusual presentation of cerebral sinus thrombosis. Vascular Medicine 2004;9(3):226-226.

Research Interest

 Research Interests:  EFC6260 (TOPIC): An international, multi-center, randomized, double-masked, placebo-controlled, parallel group study to determine the efficacy and safety of two-year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis. (Sanofi-Aventis) EFC10531 (TOWER): A multi-center, double-masked, parallel-group, placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis. (Sanofi-Aventis) OCTAGON: A randomized, double-masked, placebo-controlled, multi-center study of the effects of glatiramer acetate on the retinal nerve fiber layer and visual function in patients with a first episode of optic neuritis. (TEVA Neuroscience) A prospective case crossover study to assess whether PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for development of non-arteritic ischemic optic neuropathy (NAION). (Bayer) Idiopathic Intracranial Hypertension Treatment Trial: a randomized, double-blind placebo-controlled study of weight reduction and/or low sodium diet plus acetazolamide vs diet plus placebo in subjects with idiopathic intracranial hypertension with mild visual loss.